Used as a key intermediate in the synthesis of selective COX-2 inhibitors, particularly in the development of nonsteroidal anti-inflammatory drugs (NSAIDs). Its structure enables enhanced metabolic stability and target specificity, making it valuable in creating pharmaceuticals with reduced gastrointestinal side effects. The compound’s trifluoromethyl and sulfonyl groups contribute to improved pharmacokinetic properties, such as increased half-life and bioavailability. It is primarily employed in research and development settings for optimizing anti-inflammatory and analgesic agents.